Generated by AI
Addex Therapeutics Ltd ADR is a Swiss biopharmaceutical company focused on discovering, developing, and commercializing orally available small-molecule drugs for neurological disorders. The company specializes in allosteric modulators, a class of compounds designed to influence receptor activity in a more selective way, and its research platform centers on G-protein coupled receptors and related targets. Addex Therapeutics Ltd ADR’s current portfolio includes clinical-stage and discovery programs addressing conditions such as movement disorders, epilepsy, addiction, and other central nervous system diseases. Through this pipeline, the company plays a role in advancing innovative therapies for areas with significant unmet medical need. Addex Therapeutics Ltd ADR is based in Geneva, Switzerland, and operates as a development-stage biotechnology company with a strong emphasis on research-driven drug discovery and translational medicine.
WebsiteChemin des Mines, 9
Geneva, 1202
Switzerland
The latest articles about ADXN.
Summary of Nov 12's posts. Generated by AI.
Summary of Nov 12's posts. Generated by AI.
Summary of Nov 12's posts. Generated by AI.
Investors talking about ADXN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.